Bridging the Gap between Evidence and Clinical Practice in the Management of Acute Viral Bronchiolitis: Insights from the PRERNI-PAVB Survey Authors: Seenivasan Subramani, Muthu Chidambaram Published: 2026 Acute viral bronchiolitis (AVB) is one of the most common causes of hospital admissions in infants and young children, sometimes reaching more than 50% of total under-five admissions.1 Approximately 15–25% of them require intensive care admissions, and the outcomes are generally favorable, with mortality varying from 0.5 to 8%.1,2 Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis (50–80%), followed by rhinovirus, human metapneumovirus, influenza virus, adenovirus, coronavirus, and parainfluenza viruses.3 Most children with bronchiolitis are previously healthy; however, AVB is three times more common in preterm infants (born <30 weeks of gestation).4 Guidelines for the diagnosis and management of bronchiolitis have been published by various medical bodies and are largely similar.3,5–7 Bronchiolitis is a clinical diagnosis based on history and physical examination, and chest radiography and laboratory investigations are not routinely required. The treatment of bronchiolitis is not curative but mostly supportive. Hydration (oral or intravenous fluids) and humidified oxygen are the recommended treatment modalities.3 Inhaled bronchodilators, epinephrine, and corticosteroids had been evaluated in various studies and were not found to provide favorable outcomes. The American Academy of Pediatrics (AAP) recommends the use of inhaled hypertonic saline in hospitalized patients and not for emergency visits. Despite the availability of evidence-based guidelines, considerable variation persists in the diagnosis and management of AVB among pediatricians.3 Clinicians continue to use salbutamol (inhaled and oral), steroids (oral, inhaled, and intravenous), inhaled epinephrine, inhaled hypertonic saline, inhaled ipratropium bromide, magnesium sulfate (inhaled and intravenous), and antibiotics (oral and intravenous) in children with bronchiolitis.8 Also, the use of various investigations, like chest radiography, inflammatory markers [C-reactive protein (CRP) and procalcitonin], and polymerase chain reaction (PCR) of the respiratory samples, is quite common. The reasons for such disparity in practice may include the differences in the severity of illness at admission, need for intensive care, associated bacterial co-infections, immunocompromised status, etc. In this issue, Sahil reported the findings of an online survey on AVB, aimed at evaluating practice variations in the management of AVB across diverse healthcare settings in India.9 The Pediatric Resuscitation and Emergency Research Network of India (PRERNI)- Practice Variations in the Management of Acute Viral Bronchiolitis (PAVB) survey, a nationwide study involving 100 healthcare professionals, provides valuable insights into contemporary practice patterns and highlights the trends and challenges in the care of children with AVB. The respondents were pediatricians and pediatric intensive care physicians, predominantly working in government and private tertiary care centers. The strength of this survey was the involvement of physicians from the length and breadth of the country, representing 21 states and union territories. The survey included questions on a wide range of aspects, like upper age limit for diagnosis, admission criteria (clinical and SpO2 threshold levels), the role of radiology, PCR tests, monitoring methods, oxygen requirement, respiratory support, use of antibiotics, nebulization, steroids, need for pediatric intensive care unit (PICU) admission, length of hospital stay, etc. The upper age limit for the diagnosis of bronchiolitis is 2 years as per both AAP and National Institute for Health and Care Excellence (NICE) guidelines.3,10 However, respondents reported upper age limits ranging from 1 to 4 years, with 66% considering 2 years as the upper age limit for the diagnosis of bronchiolitis. This finding was similar to a survey on bronchiolitis by Charles Stewart conducted in the United Kingdom.11 There were significant differences in the investigations and treatment practices among respondents. About 40% of respondents reported obtaining a chest radiograph as part of the diagnostic evaluation of AVB, and 76% performed chest radiography in all children admitted with AVB. The majority of respondents were from tertiary care centers, working in PICUs. Therefore, chest radiography might have been used more frequently in children admitted to the PICU, particularly those requiring respiratory support such as high-flow nasal cannula (HFNC) therapy or invasive mechanical ventilation. Consequently, these findings may not accurately reflect the investigation practices for clinically stable children with AVB admitted to general pediatric wards. On the contrary, radiographic abnormalities in bronchiolitis often overlap with findings seen in bacterial pneumonia, creating diagnostic uncertainty and increasing the likelihood of antibiotic use. About two-thirds of respondents relied on a sepsis screen to rule out bacterial infection. Children with complicated bronchiolitis or suspected bacterial co-infections may require investigations such as CRP and procalcitonin to guide antibiotic therapy and prevent unnecessary antibiotic use. Viral PCR testing is not routinely required for the diagnosis of AVB. Identification of the etiological virus rarely influences management, as most cases are caused by RSV, rhinovirus, bocavirus, and human metapneumovirus.12 However, viral PCR testing may be useful in identifying pathogens such as the influenza virus, cytomegalovirus, and adenovirus, which may require specific treatment, particularly in immunocompromised or post-transplant patients. The survey also throws light on an underappreciated challenge: The limited use of validated severity assessment tools. Less than 40% of respondents reported using formal respiratory distress scores, with most relying solely on clinical judgment. While experienced clinicians often develop reliable bedside assessment skills, validated scoring systems facilitate objective monitoring and support consistent decisions regarding escalation and de-escalation of care. Hypertonic saline nebulization was used by about half of the respondents. Inhaled salbutamol, adrenaline, and corticosteroids were used by 10–30% of respondents. This finding highlights the mismatch between evidence and clinical practice, as physicians often face pressure to provide “some treatment” to hospitalized children with respiratory distress. However, it is reassuring to note that only 4% of respondents reported using systemic corticosteroids and chest physiotherapy in AVB. One of the most encouraging findings of the survey is the relatively restricted use of antibiotics. Most respondents reported prescribing antibiotics only sometimes or rarely, while a notable proportion never used them. In addition, several studies have evaluated interventions such as erythropoietin, caffeine, dexamethasone, optimization of protein and energy intake, ribavirin, RSV immune globulin, and diuretics in the management of severe AVB in intensive care settings.13 However, the available evidence remains insufficient to support their routine use, and current guidelines do not recommend them. Nevertheless, a significant concern remains the inconsistent implementation of evidence-based guidelines. Although many physicians reported following either the Indian Academy of Pediatrics or the AAP recommendations, only about one-third had a written institutional policy or management pathway for bronchiolitis. This lack of standardized protocols may contribute substantially to the observed variability in clinical practice. Several factors may explain the gap between evidence and clinical practice. First, most respondents (90%) were from tertiary care centers and PICUs, where children with more severe illness were frequently managed. Second, differences in disease severity at presentation and the presence of co-infections would have influenced clinical decision-making. For instance, 88% of respondents reported using HFNC. Third, the presence of comorbid conditions like congenital heart disease, immunodeficiency, or post-transplant status might have contributed to variations in the management. Continued efforts are needed to bridge the gap between evidence and clinical practice. In conclusion, the PRERNI-PAVB survey provides a valuable and timely assessment of AVB management across India. It reveals encouraging progress in supportive care and antibiotic stewardship while simultaneously exposing considerable variability in investigations, therapeutic interventions, and guideline implementation. Reducing the gap between evidence and clinical practice should remain a key priority in improving the care of children with AVB. Orcid Seenivasan Subramani https://orcid.org/0000-0002-3269-1702 Muthu Chidambaram https://orcid.org/0000-0002-4962-2463 Footnotes Source of support: Nil Conflict of interest: None References